MCM
CNSP icon

MAI Capital Management’s CNS Pharmaceuticals CNSP Stock Holding History

MAI Capital Management’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3
Closed -$8 – 2590
2026
Q1 		$8 Hold
3
– – ﹤0.01% 4978
2025
Q4 		$16 Hold
3
– – ﹤0.01% 4315
2025
Q3 		$27 Hold
3
– – ﹤0.01% 3773
2025
Q2 		$33 Hold
3
– – ﹤0.01% 3924
2025
Q1 		$55 Hold
3
– – ﹤0.01% 3384
2024
Q4 		$241 Buy
+3
New +$213 ﹤0.01% 3363

Other funds holding CNSP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return

MAI Capital Management's CNSP Position: Q2 2026 in Review

MAI Capital Management sold out of CNS Pharmaceuticals (CNSP) in Q2 2026, closing a stake of 3 shares — an estimated $8 sold.

MAI Capital Management first reported a position in CNSP in Q4 2024 and held it in 6 quarters. The position peaked at $241 in Q4 2024. 11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

  • MAI Capital Management reported no remaining CNS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • MAI Capital Management sold 3 CNS Pharmaceuticals shares in Q2 2026, an estimated $8.
  • MAI Capital Management first reported a position in CNS Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • MAI Capital Management's CNS Pharmaceuticals position peaked at $241 in Q4 2024.
  • 11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.